SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 171,017.77 |
Enterprise Value ($M) | 240,476.77 |
Book Value ($M) | 89,288.00 |
Book Value / Share | 15.76 |
Price / Book | 1.92 |
NCAV ($M) | -86,122.00 |
NCAV / Share | -15.20 |
Price / NCAV | -1.99 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.00 |
Return on Assets (ROA) | -0.00 |
Return on Equity (ROE) | -0.00 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 0.78 |
Current Ratio | 1.05 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 42,415.00 |
Assets | 221,095.00 |
Liabilities | 128,537.00 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 58,496.00 |
Operating Income | 5,259.00 |
Net Income | 2,119.00 |
Earnings Per Share Diluted | n/a |
Earnings Per Share Basic | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 8,700.00 |
Cash from Investing | -32,278.00 |
Cash from Financing | 26,066.00 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Vanguard Group Inc | 8.97 | 0.97 | |
13G/A | State Street Corp | 5.10 | 1.03 | |
13G/A | BlackRock Inc. | 7.70 | -1.83 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
3,782,384 | 29,942,463 | 12.63 | |
4,638,636 | 33,808,443 | 13.72 | |
2,705,700 | 22,721,287 | 11.91 | |
3,094,139 | 17,210,308 | 17.98 | |
3,685,373 | 23,440,457 | 15.72 | |
(click for more detail) |
Similar Companies | |
---|---|
NUVB – Nuvation Bio Inc. | OGN – Organon & Co. |
PBH – Prestige Consumer Healthcare Inc. | PRGO – Perrigo Company plc |
QGEN – Qiagen N.V. |
Financial data and stock pages provided by
Fintel.io